Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1988 Feb;26(1):1–10. doi: 10.1007/BF00199840

Cytolytic antitumor effector cells in long-term cultures of human tumor-infiltrating lymphocytes in recombinant interleukin 2

Theresa L Whiteside 1,2,✉, D S Heo 2, S Takagi 2, J T Johnson 4,2, S Iwatsuki 5,2, R B Herberman 1,6,2
PMCID: PMC11038070  PMID: 3257898

Abstract

Lymphocytes infiltrating human solid tumors (TIL) and autologous peripheral blood lymphocytes (A-PBL) were cultured with 1000 units/ml of recombinant interleukin 2 (rIL2) in long-term cultures. TIL isolated from 26 primary squamous cell carcinomas of the head and neck expanded better (P<0.01) and achieved higher total lytic units of activity against fresh tumor cell targets (P<0.05) than A-PBL. TIL obtained from primary hepatocellular carcinomas (n=7) showed a higher degree of expansion than those from metastatic liver tumors (n=7). Further, TIL from metastatic tumors of the head and neck, liver, and ovary were delayed up to 50 days in their proliferative response to rIL2. Long-term mass cultures in rIL2 of TIL, A-PBL, or normal PBL were serially monitored for cytotoxicity with different cultured and fresh tumor cell targets and for phenotypic markers of the predominating cell populations. Antitumor cytotoxicity was found in cultures enriched in CD3 + Leu19 + and/or CD3-Leu19 + cells. Two-color sorting of such cultures followed by cytotoxicity assays confirmed that the human antitumor effectors expressed either the CD3 + Leu19 + or CD3-Leu19 + phenotype. CD3 + Leu19- cells had little or no antitumor cytotoxicity. The two types of Leu19 + effector cells were present in low numbers in fresh TIL, A-PBL, or normal PBL; in contrast, in some rIL2-expanded long-term cultures, they represented a majority of proliferating cells. This study identifies for the first time two types of antitumor effector cells in rIL2 cultures of human TIL, one of which may represent activated natural killer cells on the basis of the absence of the CD3 and expression of the Leu19 antigen. These antitumor effector cells mediate non-MHC-restricted cytotoxicity of fresh or cultured tumor cell targets of different histologic types.

Keywords: Human Solid Tumor, Culture Tumor Cell, Primary Hepatocellular Carcinoma, Metastatic Liver Tumor, Antitumor Effector

References

  • 1.Brunner KT, MacDonald HR, Cerottini J-C. Quantitation and clonal isolation of cytotoxic T lymphocyte precursors selectively infiltrating murine sarcoma virus-induced tumors. J Exp Med. 1981;154:362–373. doi: 10.1084/jem.154.2.362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. Lysis of natural killer resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982;155:1823–1841. doi: 10.1084/jem.155.6.1823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Heo DS, Whiteside TL, Johnson JT, Chen K, Barnes EL, Herberman RB (1987) Long-term interleukin 2-dependent growth and cytotoxic activity of tumor-infiltrating lymphocytes (TIL) from human squamous cell carcinomas of the head and neck. Cancer Res (in press) [PubMed]
  • 4.Hutchinson GH, Heinemann D, Symes MO, Williamson RCN. Differential immune reactivity of tumor-intrinsic and peripheral blood lymphocytes against colorectal carcinoma cells. Br J Cancer. 1981;44:396–402. doi: 10.1038/bjc.1981.197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Kurnick JT, Kradin RL, Blumberg R, Schneeberger EE, Boyle LA. Functional characterization of T lymphocytes propagated from human lung carcinomas. Clin Immunol Immunopathol. 1986;38:367–380. doi: 10.1016/0090-1229(86)90247-3. [DOI] [PubMed] [Google Scholar]
  • 6.Lanier LL, Le AM, Civin CI, Loken MK, Phillips JH. The relationship of CD16 (Leu11) and Leu19 (NKH-1) antigen expression on human peripheral blood, NK cells and cytotoxic T lymphocytes. J Immunol. 1986;136:4480–4486. [PubMed] [Google Scholar]
  • 7.Lanier LL, Le AM, Cwirla S, Federspiel N, Phillips JH. Antigenic, functional, and molecular genetic studies of human natural killer cells and cytotoxic T lymphocytes not restricted by the major histocompatibility complex. Fed Proc. 1986;45:2823–2828. [PubMed] [Google Scholar]
  • 8.Lanier LL, Le AM, Ding A, Evans EL, Krensky AM, Clayberger C, Phillips JH. Expression of Leu-19 (NKH-1) antigen on IL 2-dependent cytotoxic and non-cytotoxic T cell lines. J Immunol. 1987;138:2019–2023. [PubMed] [Google Scholar]
  • 9.Miescher S, Whiteside TL, Carrel S, von Fliedner V. Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors. I. Effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J Immunol. 1986;136:1899–1907. [PubMed] [Google Scholar]
  • 10.Miescher S, Stoeck M, Whiteside TL, Leyvraz S et al. (1987) Altered activation pathways in T lymphocytes infiltrating human solid tumors. Transpl Proc (in press) [PubMed]
  • 11.Moy PM, Holmes EC, Golub SH. Depression of natural killer cytotoxic activity in lymphocytes infiltrating human pulmonary tumors. Cancer Res. 1985;45:57–60. [PubMed] [Google Scholar]
  • 12.Mule JJ, Hellstrom I, Hellstrom KE. Cell surface phenotypes of radio-labeled immune long-lived lymphocytes that selectively localize in syngeneic tumors. Am J Pathol. 1982;107:142–149. [PMC free article] [PubMed] [Google Scholar]
  • 13.Muul LM, Spiess PJ, Director EP, Rosenberg SA. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol. 1987;138:989–995. [PubMed] [Google Scholar]
  • 14.Phillips JH, Gemlo BT, Myers WW, Rayner AA, Lanier LL. Lysis of solid tumor cell targets by in vivo and in vitro activated natural killer cells: Clinical and experimental studies. Fed Proc. 1987;46:1027. [Google Scholar]
  • 15.Pross HF, Baines MG, Rubin P, Shragge P, Patterson MS. Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity. J Clin Immunol. 1981;1:51–63. doi: 10.1007/BF00915477. [DOI] [PubMed] [Google Scholar]
  • 16.Rosenberg SA, Spiess P, Lafreniere A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986;233:1318–1321. doi: 10.1126/science.3489291. [DOI] [PubMed] [Google Scholar]
  • 17.Roth JA, Grimm EA, Gupta RK, Ames RS. Immunoregulatory factors derived from human tumors. J Immunol. 1982;128:1955–1962. [PubMed] [Google Scholar]
  • 18.Schmidt RE, Murray C, Daley JF, Schlossman SF, Ritz J. A subset of natural killer cells in peripheral blood displays a mature T cell phenotype. J Exp Med. 1986;164:351–356. doi: 10.1084/jem.164.1.351. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Taramelli D, Fossati G, Balsari A, Marolda K, Parmiani R. The inhibition of lymphocyte stimulation by autologous human metastatic melanoma cells correlates with the expression of HLA-DR antigens on the tumor cells. Int J Cancer. 1984;34:797–806. doi: 10.1002/ijc.2910340610. [DOI] [PubMed] [Google Scholar]
  • 20.von Fliedner V, Qiao L, Whiteside TL, Leyvraz S, Barras C, Miescher S. Clonogenic and functional potential of T lymphocytes infiltrating human solid tumors. In: Truitt RL, Gale RP, Bortin MM, editors. Cellular immunotherapy of cancer. New York, NY: Alan Liss; 1987. [PubMed] [Google Scholar]
  • 21.Vose BM, Bonnard GD. Specific cytotoxicity against autologous tumor and proliferative responses of human lymphocytes grown in interleukin-2. Int J Cancer. 1982;29:33–39. doi: 10.1002/ijc.2910290107. [DOI] [PubMed] [Google Scholar]
  • 22.Vose BM, Moore M. Human tumor-infiltrating lymphocytes: A marker of host response. Semin Hematol. 1985;22:27–40. [PubMed] [Google Scholar]
  • 23.Whiteside TL, Miescher S, Hurlimann J, Moretta L, von Fliedner V. Separation, phenotyping and limiting dilution analysis of T lymphocytes infiltrating human solid tumors. Int J Cancer. 1986;37:803–811. doi: 10.1002/ijc.2910370602. [DOI] [PubMed] [Google Scholar]
  • 24.Whiteside TL, Miescher S, Hurlimann J, Moretta L, von Fliedner V. Clonal analysis and in situ characterization of lymphocytes infiltrating human breast carcinomas. Cancer Immunol Immunother. 1986;23:169–178. doi: 10.1007/BF00205646. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Whiteside TL, Heo DS, Chen K, Adler A, Johnson JT, Herberman RB. Expansion of tumor-infiltrating lymphocytes from human solid tumors in interleukin-2. In: Truitt RL, Gale RP, Bortin MM, editors. Cellular immunotherapy of cancer. New York, NY: Alan Liss; 1987. [PubMed] [Google Scholar]
  • 26.Whiteside TL, Heo DS, Takagi S, Herberman RB (1987) Characterization of novel antitumor effector cells in long-term cultures of human tumor-infiltrating lymphocytes. Transplant Proc (in press) [PubMed]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES